These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 37555318)

  • 21. ID1-induced p16/IL6 axis activation contributes to the resistant of hepatocellular carcinoma cells to sorafenib.
    Niu LL; Cheng CL; Li MY; Yang SL; Hu BG; Chong CCN; Chan SL; Ren J; Chen GG; Lai PBS
    Cell Death Dis; 2018 Aug; 9(9):852. PubMed ID: 30154433
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Valproic acid reverses sorafenib resistance through inhibiting activated Notch/Akt signaling pathway in hepatocellular carcinoma.
    Yang X; Liu J; Liang Q; Sun G
    Fundam Clin Pharmacol; 2021 Aug; 35(4):690-699. PubMed ID: 33015852
    [TBL] [Abstract][Full Text] [Related]  

  • 23. COX-2/PGE2 Axis Regulates HIF2α Activity to Promote Hepatocellular Carcinoma Hypoxic Response and Reduce the Sensitivity of Sorafenib Treatment.
    Dong XF; Liu TQ; Zhi XT; Zou J; Zhong JT; Li T; Mo XL; Zhou W; Guo WW; Liu X; Chen YY; Li MY; Zhong XG; Han YM; Wang ZH; Dong ZR
    Clin Cancer Res; 2018 Jul; 24(13):3204-3216. PubMed ID: 29514844
    [No Abstract]   [Full Text] [Related]  

  • 24. Hepatocellular Carcinoma and Nuclear Paraspeckles: Induction in Chemoresistance and Prediction for Poor Survival.
    Kessler SM; Hosseini K; Hussein UK; Kim KM; List M; Schultheiß CS; Schulz MH; Laggai S; Jang KY; Kiemer AK
    Cell Physiol Biochem; 2019; 52(4):787-801. PubMed ID: 30946555
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Identification of hepatic fibrosis inhibitors through morphometry analysis of a hepatic multicellular spheroids model.
    Song Y; Kim S; Heo J; Shum D; Lee SY; Lee M; Kim AR; Seo HR
    Sci Rep; 2021 May; 11(1):10931. PubMed ID: 34035369
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacogenetics of the systemic treatment in advanced hepatocellular carcinoma.
    De Mattia E; Cecchin E; Guardascione M; Foltran L; Di Raimo T; Angelini F; D'Andrea M; Toffoli G
    World J Gastroenterol; 2019 Aug; 25(29):3870-3896. PubMed ID: 31413525
    [TBL] [Abstract][Full Text] [Related]  

  • 27. DNMT3b/OCT4 expression confers sorafenib resistance and poor prognosis of hepatocellular carcinoma through IL-6/STAT3 regulation.
    Lai SC; Su YT; Chi CC; Kuo YC; Lee KF; Wu YC; Lan PC; Yang MH; Chang TS; Huang YH
    J Exp Clin Cancer Res; 2019 Nov; 38(1):474. PubMed ID: 31771617
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The BAFF/NFκB axis is crucial to interactions between sorafenib-resistant HCC cells and cancer-associated fibroblasts.
    Gao L; Morine Y; Yamada S; Saito Y; Ikemoto T; Tokuda K; Miyazaki K; Okikawa S; Takasu C; Shimada M
    Cancer Sci; 2021 Sep; 112(9):3545-3554. PubMed ID: 34159680
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inactivation of Transcriptional Repressor Capicua Confers Sorafenib Resistance in Human Hepatocellular Carcinoma.
    Hashiba T; Yamashita T; Okada H; Nio K; Hayashi T; Asahina Y; Hayashi T; Terashima T; Iida N; Takatori H; Shimakami T; Kawaguchi K; Arai K; Sakai Y; Yamashita T; Mizukoshi E; Takamura H; Ohta T; Honda M; Kaneko S
    Cell Mol Gastroenterol Hepatol; 2020; 10(2):269-285. PubMed ID: 32169577
    [TBL] [Abstract][Full Text] [Related]  

  • 30. PPARδ Reprograms Glutamine Metabolism in Sorafenib-Resistant HCC.
    Kim MJ; Choi YK; Park SY; Jang SY; Lee JY; Ham HJ; Kim BG; Jeon HJ; Kim JH; Kim JG; Lee IK; Park KG
    Mol Cancer Res; 2017 Sep; 15(9):1230-1242. PubMed ID: 28584024
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Target immune components to circumvent sorafenib resistance in hepatocellular carcinoma.
    Wei S; Wei F; Li M; Yang Y; Zhang J; Li C; Wang J
    Biomed Pharmacother; 2023 Jul; 163():114798. PubMed ID: 37121146
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Burning down the house: Pyroptosis in the tumor microenvironment of hepatocellular carcinoma.
    Cheng C; Hsu SK; Chen YC; Liu W; Shu ED; Chien CM; Chiu CC; Chang WT
    Life Sci; 2024 Jun; 347():122627. PubMed ID: 38614301
    [TBL] [Abstract][Full Text] [Related]  

  • 33. EPHB2 Activates β-Catenin to Enhance Cancer Stem Cell Properties and Drive Sorafenib Resistance in Hepatocellular Carcinoma.
    Leung HW; Leung CON; Lau EY; Chung KPS; Mok EH; Lei MML; Leung RWH; Tong M; Keng VW; Ma C; Zhao Q; Ng IOL; Ma S; Lee TK
    Cancer Res; 2021 Jun; 81(12):3229-3240. PubMed ID: 33903122
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Exosomes derived from HCC cells induce sorafenib resistance in hepatocellular carcinoma both in vivo and in vitro.
    Qu Z; Wu J; Wu J; Luo D; Jiang C; Ding Y
    J Exp Clin Cancer Res; 2016 Sep; 35(1):159. PubMed ID: 27716356
    [TBL] [Abstract][Full Text] [Related]  

  • 35. High expression of HOXA13 correlates with poorly differentiated hepatocellular carcinomas and modulates sorafenib response in in vitro models.
    Quagliata L; Quintavalle C; Lanzafame M; Matter MS; Novello C; di Tommaso L; Pressiani T; Rimassa L; Tornillo L; Roncalli M; Cillo C; Pallante P; Piscuoglio S; Ng CK; Terracciano LM
    Lab Invest; 2018 Jan; 98(1):95-105. PubMed ID: 29035381
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Liver X Receptor Agonism Sensitizes a Subset of Hepatocellular Carcinoma to Sorafenib by Dual-Inhibiting MET and EGFR.
    Shao W; Zhu W; Lin J; Luo M; Lin Z; Lu L; Jia H; Qin L; Lu M; Chen J
    Neoplasia; 2020 Jan; 22(1):1-9. PubMed ID: 31751859
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sorafenib resistance in hepatocarcinoma: role of hypoxia-inducible factors.
    Méndez-Blanco C; Fondevila F; García-Palomo A; González-Gallego J; Mauriz JL
    Exp Mol Med; 2018 Oct; 50(10):1-9. PubMed ID: 30315182
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Induction of IL-6Rα by ATF3 enhances IL-6 mediated sorafenib and regorafenib resistance in hepatocellular carcinoma.
    Dai Z; Wang X; Peng R; Zhang B; Han Q; Lin J; Wang J; Lin J; Jiang M; Liu H; Lee TH; Lu KP; Zheng M
    Cancer Lett; 2022 Jan; 524():161-171. PubMed ID: 34687791
    [TBL] [Abstract][Full Text] [Related]  

  • 39. TNF-α is a potential therapeutic target to overcome sorafenib resistance in hepatocellular carcinoma.
    Tan W; Luo X; Li W; Zhong J; Cao J; Zhu S; Chen X; Zhou R; Shang C; Chen Y
    EBioMedicine; 2019 Feb; 40():446-456. PubMed ID: 30594557
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hypoxia-mediated sorafenib resistance can be overcome by EF24 through Von Hippel-Lindau tumor suppressor-dependent HIF-1α inhibition in hepatocellular carcinoma.
    Liang Y; Zheng T; Song R; Wang J; Yin D; Wang L; Liu H; Tian L; Fang X; Meng X; Jiang H; Liu J; Liu L
    Hepatology; 2013 May; 57(5):1847-57. PubMed ID: 23299930
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.